This live meeting series is designed specifically for clinicians who treat and manage veterans with lung cancer. Keep up to date on the latest information on immunotherapy, patient identification, adverse event management, and treatment selection and engage with an immunotherapy expert via a case presentation and discussion.
1.0 AMA PRA Category 1 Credit™
|5 min||Test Your Knowledge|
|5 min||Understanding how checkpoint inhibitors work|
|18 min||Treatment strategies that incorporate checkpoint inhibitors in lung cancer|
|7 min||Adverse events of immune checkpoint inhibitors|
|8 min||Interactive cases|
|5 min||What have you learned?|
|7 min||Take-aways, Q & A, Conclusion|
This educational activity is designed to meet the needs of medical, surgical, and radiation oncologists, as well as advanced practitioners and midlevel providers, who treat/manage patients with lung cancer in the VA system or in the VA choice programs.
After successful completion of this educational activity, participants should be able to:
- Understand key components of the immune system and the biochemistry associated with checkpoint blockade, including specific inhibitors of PD-1/PD-L1 and CTLA-4
- Implement effective strategies for integrating checkpoint inhibitors into the treatment of non-small cell lung cancer (NSCLC)
- Develop treatment plans to manage both common and rare immune-related adverse events (irAEs) associated with the use of checkpoint inhibitors in lung cancer
This educational activity is supported by a grant from Merck and Co, Inc.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Post Graduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.
Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact us prior to the live event using our contact form.
There is no fee for this activity.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.